1 |
Maier S, Nimmrich I, Koenig, T et al (2007). DNA-methylation of the homeodomain transcription factor PITX2 reliably predicts risk of distant disease recurrence in tamoxifentreated, node-negative breast cancer patients--Technical and clinical validation in a multi-centre setting in collaboration with the European Organisation for Research and Treatment of Cancer (EORTC) PathoBiology group. Eur J Cancer, 43, 1679-86.
DOI
|
2 |
Nimmrich I, Sieuwerts AM, Meijer-van Gelder ME et al (2008). DNA hypermethylation of PITX2 is a marker of poor prognosis in untreated lymph node-negative hormone receptor-positive breast cancer patients. Breast Cancer Res Treat, 111, 429-37.
DOI
|
3 |
Somali I, Ustaoglu BY, Tarhan MO, et al (2013). Clicopathologic and demographic evaluation of triple negative breast cancer patients among a turkish patient population: a single center experience. Asian Pac J Cancer Prev, 14, 6013-7
DOI
ScienceOn
|
4 |
Widschwendter M, Apostolidou S, Raum E, et al (2008). Epigenotyping in peripheral blood cell DNA and breast cancer risk: a proof of principle study. PLoS ONE, 3, 2656.
DOI
|
5 |
Yip CH, Taib NA & Mohamed I (2006). Epidemiology of breast cancer in Malaysia. Asian Pac J Cancer Prev, 7, 369-74.
|
6 |
Zubeda S, Kaipa PR, Shaik NA, et al (2013). HER-2/neu status: A neglected marker of prognostication and management of breast cancer patients in India. Asian Pac J Cancer Prev, 14, 2231-5.
DOI
ScienceOn
|
7 |
Ellis IO and Bartlett J (2004). Best Practice No. 176: updated recommendations for HER2 testing in the UK. J Clin Pathol, 57, 233-7.
DOI
|
8 |
Allred DC and Berardo HJ (1998). Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol, 11, 155-68.
|
9 |
Ambroise M, Ghosh M, Mallikarjuna VS, Kurtian A (2011). Immunohistochemical profile of breast cancer patients at a tertiary care hospital in South India. Asian Pac J Cancer Prev, 12, 625-9.
|
10 |
Das PM and Singal R (2004). DNA methylation and cancer. J Clin Oncol, 22, 4632-42.
DOI
ScienceOn
|
11 |
Harvey JM, Clark GM, Osborne CK & Allred DC (1999). Estrogen receptor status by immunohistochemistry is Superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol, 17, 1474.
|
12 |
Esteller M (2008). Epigenetics in cancer. N Engl J Med, 358, 1148-59.
DOI
ScienceOn
|
13 |
Hasnan J, Suhaila A, Mogana DM, Fauziah MI (2012). Expression of Bax and Bcl-2 in tumour cells and blood vessels of breast cancer and their association with angiogenesis and hormonal receptors. Asian Pac J Cancer Prev, 13, 3857-62.
DOI
ScienceOn
|
14 |
Harbeck N, Nimmrich I, Hartmann A, et al (2008). Multicenter study using paraffin-embedded tumor tissue testing PITX2 DNA methylation as a marker for outcome prediction in tamoxifen-treated, node-negative breast cancer patients. J Clin Oncol, 26, 5036-42.
DOI
|
15 |
Li CY, Zhang S, Zhang XB, et al (2013). Clinicopathological and prognostic characteristics of triple-negative breast cancer (TNBC) in Chinese patients: A retrospective study. Asian Pac J Cancer Prev, 14, 3779-84.
DOI
ScienceOn
|
16 |
Ma KK, Chau WW, Wong CHN, et al (2012). Triple negative status is a poor prognostic indicator in chinese women with breast cancer: a ten year review. Asian Pac J Cancer Prev, 13, 2109-14.
DOI
ScienceOn
|
17 |
Tanner M, Gancberg D, Di Leo A, et al (2000). Chromogenic in situ hybridization: a practical alternative for fluorescence in situ hybridization: a practical alternative for fluorescence in situ hybridization to detect HER-2/neu oncogene amplification in archival breast cancer samples. Am J Pathol, 157, 1467-72.
DOI
ScienceOn
|